Biogen Idec Inc (BIIB): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Biogen Idec ( BIIB) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.6%. By the end of trading, Biogen Idec rose $3.40 (1.6%) to $211.48 on light volume. Throughout the day, 606,310 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1,453,800 shares. The stock ranged in a price between $208.01-$212.77 after having opened the day at $208.35 as compared to the previous trading day's close of $208.08. Other companies within the Drugs industry that increased today were: Ambit Biosciences ( AMBI), up 25.5%, Horizon Pharma ( HZNP), up 20.8%, GW Pharmaceuticals PLC ADR ( GWPH), up 15.4% and Ocera Therapeutics ( OCRX), up 13.0%.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $49.1 billion and is part of the health care sector. Shares are up 41.1% year to date as of the close of trading on Wednesday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Mast Therapeutics ( MSTX), down 43.4%, Oxygen Biotherapeutics ( OXBT), down 5.0%, Inovio Pharmaceuticals ( INO), down 4.8% and Santarus ( SNTS), down 4.3% , were all laggards within the drugs industry with Salix Pharmaceuticals ( SLXP) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

It's a Flash Sale!: Cramer's 'Mad Money' Recap (Wednesday 1/31/18)

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

Building in Biotech, Adding to Twitter

Building in Biotech, Adding to Twitter

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI

Biogen, Celgene Jump on Earnings; Ford's Acquisitions Fail to Move Stock--ICYMI